(Albany, US), September 29, 2026 – DelveInsight’s report “Diabetic Foot Ulcer Market Insights, Epidemiology and Market Forecast – 2036” delivers an in-depth understanding of the Diabetic Foot Ulcer (DFU) landscape, presenting historical and forecasted epidemiology along with the Diabetic Foot Ulcer therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The report offers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It highlights key unmet medical needs in Diabetic Foot Ulcer and maps the competitive and clinical landscape to uncover high-value opportunities.
Request a sample to unlock the CAGR for the Diabetic Foot Ulcer Market Forecast: https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-dfus-market
Some of the key facts of the Diabetic Foot Ulcer Market Report:
The Diabetic Foot Ulcer market size was valued at approximately USD 2.5 billion in 2025 and is anticipated to witness significant growth during the forecast period, expanding at a CAGR of 10% from 2026 to 2036.
According to the estimates, the largest market size of Diabetic Foot Ulcer was captured by the United States, at approximately USD 2,300 million in 2025.
According to DelveInsight’s estimates, the total prevalent cases of Diabetic Foot Ulcer in the 7MM were approximately 6,600,000 in 2025.
In the US, there were approximately 5,060,000 prevalent cases of Diabetic Foot Ulcer in 2025.
In September 2025, RION partnered with Lonza to enable cGMP manufacturing and scale-up of its PEP exosome therapy, leveraging Lonza’s expertise and Houston facility to support late-stage clinical supply and future commercial production.
In June 2025, Eluciderm received US FDA IND clearance for ELU42, a topical Wnt modulator with bacteriostatic properties, and announced the initiation of a Phase I/IIa trial in August 2025 across three US sites (n = 15) to evaluate safety and efficacy in diabetic foot ulcers, with data expected to support Phase II development in 2026 and potential Breakthrough Therapy designation by 2027.
In March 2025, Lynch Regenerative Medicine acquired exclusive rights to REGRANEX gel and recombinant PDGF from Smith & Nephew, to expand its use beyond diabetic foot ulcers into broader soft tissue regeneration and aesthetic wound healing.
In January 2025, RION announced completion of patient enrollment in its Phase II trial of PEP (Purified Exosome Product) for Diabetic Foot Ulcer, building on encouraging Phase 1B safety and efficacy data; the company plans to advance to a Phase III study and pursue a BLA filing with the FDA if results are successful.
OMNIGRAFT Dermal Regeneration Matrix and Becaplermin (REGRANEX) have been approved by the FDA for the treatment of Diabetic Foot Ulcer.
Key Diabetic Foot Ulcer Companies: Integra Life Sciences, Lynch Regenerative Medicine, Smith & Nephew, Rion, RHEACELL GmbH, FGK Clinical Research GmbH, Ticeba GmbH, Eluciderm, and others.
Key Diabetic Foot Ulcer Therapies: OMNIGRAFT Dermal Regeneration Matrix, Becaplermin (REGRANEX) Gel, PEP-TISSEEL, Allo-APZ2-Diabetic Foot Ulcer, ELU42, among others.
Diabetic Foot Ulcer Overview
Diabetic Foot Ulcer is a serious and common complication of diabetes, arising from a combination of peripheral neuropathy, peripheral arterial disease, and impaired wound healing. It occurs when minor trauma or pressure on the foot goes unnoticed due to loss of sensation, leading to skin breakdown and chronic ulcer formation. Diabetic Foot Ulcers can range from superficial wounds to deep ulcers involving muscle and bone, often accompanied by infection in advanced stages.
Common symptoms include non-healing wounds, redness, swelling, discharge, and, in severe cases, tissue necrosis. Diabetic Foot Ulcer is primarily caused by prolonged hyperglycemia, poor circulation, and repetitive mechanical stress.
To know in detail about the Diabetic Foot Ulcer market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Diabetic Foot Ulcer Market Forecast
Diabetic Foot Ulcer Diagnosis and Treatment Algorithm
Diabetic Foot Ulcer is diagnosed through clinical examination and supportive tests, often detected during routine foot checks in diabetic patients. Physical assessment focuses on ulcer size, depth, infection signs, and evaluation of neuropathy and blood circulation. Blood tests such as glucose levels and HbA1c assess glycemic control, while imaging (X-ray or MRI) may be used to detect deep infection or osteomyelitis. Vascular tests like ankle-brachial index (ABI) help identify poor blood flow, and wound cultures may be performed to guide treatment in infected ulcers.
The primary goals of Diabetic Foot Ulcer treatment are to promote wound healing, prevent infection and lower-extremity amputation, and address contributing factors such as hyperglycemia, peripheral ischemia, and pressure-related tissue injury. Standard management includes regular wound debridement, pressure offloading using total contact casts or therapeutic footwear, and appropriate infection control with systemic antibiotics selected according to infection severity and microbiological findings. Commonly used agents include amoxicillin–clavulanate and clindamycin, while broad-spectrum therapies such as piperacillin–tazobactam may be required in severe infections.
Advanced or adjunctive therapies include negative pressure wound therapy (NPWT), growth factor–based treatments such as becaplermin, and bioengineered skin substitutes including Apligraf and Dermagraft. In patients with peripheral arterial disease, revascularization procedures such as angioplasty or bypass surgery may be necessary to restore tissue perfusion. In addition, optimal glycemic control through individualized antidiabetic therapy is essential for improving healing outcomes and reducing ulcer recurrence.
In the US, practices include surgical debridement, dressings, wound off-loading, vascular assessment, and infection control. In Europe, antibiotic therapy, wound off-loading, and surgical management are standard.
Diabetic Foot Ulcer Unmet Needs
Despite advances in Diabetic Foot Ulcer management and secondary prevention strategies, recurrence rates remain unacceptably high, with many ulcers recurring within months after apparent healing despite successful wound closure. Key gaps include:
Delayed and inaccurate diagnosis
Significant impact on quality of life (QoL)
Complications in high-risk populations
Limitations of existing treatment options, and others
Diabetic Foot Ulcer Epidemiology
The epidemiology section of the Diabetic Foot Ulcer market report provides insights about the historical and current patient pool and forecasted trends for the seven major countries. Key findings include:
Among the EU4, Italy accounted for the highest number of prevalent cases of Diabetic Foot Ulcer, followed by Germany, whereas Spain accounted for the lowest number of cases in 2025.
The observed male predominance and earlier onset of Diabetic Foot Ulcer highlight the importance of early risk stratification, routine foot screening, and targeted preventive care strategies in high-risk populations to reduce complications and improve outcomes.
A significant proportion of the Diabetic Foot Ulcer burden is associated with comorbid conditions such as diabetes mellitus, peripheral arterial disease (PAD), peripheral neuropathy, chronic kidney disease, obesity, and infection risk, with peripheral neuropathy and ischemia being the primary drivers of ulcer formation.
Download the report to understand which factors are driving Diabetic Foot Ulcer epidemiology trends @ Diabetic Foot Ulcer Epidemiology Forecast
Diabetic Foot Ulcer Market Outlook
The Diabetic Foot Ulcer market is undergoing a meaningful shift, moving beyond conventional wound care approaches such as debridement, offloading, and standard dressings toward advanced, mechanism-driven therapies that actively promote tissue regeneration and healing. Increasing adoption of biologics, growth factors, skin substitutes, and emerging modalities such as exosome-based therapies and cell-based treatments reflects a transition toward more targeted and effective interventions.
The United States remains the largest Diabetic Foot Ulcer market, driven by high disease prevalence, advanced healthcare infrastructure, strong reimbursement frameworks, and rapid uptake of innovative wound care technologies compared with Europe and other regions. Europe and Japan demonstrate steady growth, supported by rising diabetes prevalence, increasing awareness of chronic wound management, and gradual uptake of innovative therapies.
The management of Diabetic Foot Ulcers remains particularly challenging owing to impaired wound healing, poor treatment adherence, and inconsistent implementation of evidence-based guidelines. The latest International Working Group on the Diabetic Foot (IWGDF) guidelines therefore recommend that selected adjunctive therapies be considered in patients whose ulcers fail to heal despite optimal standard care.
Discover more about therapies set to grab major Diabetic Foot Ulcer market share @ Diabetic Foot Ulcer Treatment Landscape
Diabetic Foot Ulcer Drug Chapters
Approved Diabetic Foot Ulcer Therapies
OMNIGRAFT Dermal Regeneration Matrix: Integra Life Sciences
OMNIGRAFT Dermal Regeneration Matrix, developed by Integra Life Sciences, is a bilayer bioengineered skin substitute approved by the US FDA for the treatment of chronic Diabetic Foot Ulcers lasting longer than six weeks. It promotes wound healing by providing a collagen-based scaffold that supports tissue regeneration, cellular infiltration, and new blood vessel formation. OMNIGRAFT is used alongside standard wound care measures such as debridement, infection control, and offloading.
Becaplermin (REGRANEX) Gel: Lynch Regenerative Medicine (Smith & Nephew)
Becaplermin (REGRANEX) Gel, marketed by Lynch Regenerative Medicine (Smith & Nephew), is a topical recombinant human Platelet-Derived Growth Factor (PDGF) approved by the US FDA in 1997 for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue. It promotes wound healing by stimulating chemotaxis and proliferation of cells involved in tissue repair, thereby enhancing granulation tissue formation. Its use has been moderated due to safety considerations and the need for careful patient selection. In July 2012, the European Commission withdrew the marketing authorization for REGRANEX following the manufacturer’s voluntary withdrawal request for commercial reasons.
Emerging Diabetic Foot Ulcer Therapies
PEP-TISSEEL: Rion
PEP-TISSEEL, developed by Rion, is a topical fibrin-based biological sealant designed to support wound healing in conditions such as diabetic foot ulcers and other chronic wounds. It mimics the final stages of the coagulation cascade by combining fibrinogen and thrombin to form a stable fibrin clot at the application site. This clot acts as a temporary extracellular matrix, promoting cell migration, angiogenesis, and tissue regeneration.
Allo-APZ2-Diabetic Foot Ulcer: RHEACELL GmbH / FGK Clinical Research GmbH / Ticeba GmbH
Allo-APZ2-Diabetic Foot Ulcer is an advanced cell-based therapy composed of allogeneic ABCB5-positive mesenchymal stromal cells (MSCs) derived from human skin. It is being investigated for the treatment of chronic, non-healing Diabetic Foot Ulcers, leveraging the immunomodulatory, anti-inflammatory, and pro-angiogenic properties of ABCB5+ MSCs to promote tissue regeneration and wound healing.
ELU42: Eluciderm
ELU42 is a novel small molecule Wnt pathway modulator with bacteriostatic and regenerative properties, aimed at accelerating wound healing and reducing infection burden in Diabetic Foot Ulcer patients.
Key Factors Driving the Diabetic Foot Ulcer Market
Rising Diabetic Foot Ulcer Prevalence: The increasing prevalence of Diabetic Foot Ulcer, particularly among males, is a primary driver of market expansion. In the US, in 2025, there were approximately 5,060,000 prevalent cases of Diabetic Foot Ulcer.
Rising Opportunities in Advanced Diabetic Foot Ulcer Therapies: Innovative therapies such as biologics, skin substitutes, and regenerative agents are creating opportunities by improving wound healing and reducing complications compared to standard care.
Emerging Diabetic Foot Ulcer Competitive Landscape: The Diabetic Foot Ulcer pipeline is evolving with agents like PEP-TISSEEL, Allo-APZ2-Diabetic Foot Ulcer, and ELU42, focusing on wound healing and regeneration, though unmet needs in efficacy and infection control remain.
To know more about Diabetic Foot Ulcer companies working in the treatment market, visit @ Diabetic Foot Ulcer Clinical Trials and Therapeutic Assessment
Scope of the Diabetic Foot Ulcer Market Report
Study Period: 2022–2036
Forecast Period: 2026–2036
Geographies Covered: The US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan
Key Diabetic Foot Ulcer Companies: Integra Life Sciences, Lynch Regenerative Medicine, Smith & Nephew, Rion, RHEACELL GmbH, FGK Clinical Research GmbH, Ticeba GmbH, Eluciderm, and others
Key Diabetic Foot Ulcer Therapies: OMNIGRAFT Dermal Regeneration Matrix, Becaplermin (REGRANEX) Gel, PEP-TISSEEL, Allo-APZ2-Diabetic Foot Ulcer, ELU42, and others
Diabetic Foot Ulcer Market Segmentation: By region/geographies and by drugs/therapies
Table of Contents
Key Insights
Report Introduction
Executive Summary of Diabetic Foot Ulcer
Key Events of Diabetic Foot Ulcer
Epidemiology and Market Forecast Methodology of Diabetic Foot Ulcer
Diabetic Foot Ulcer Market Overview at a Glance
Disease Background and Overview of Diabetic Foot Ulcer
Diabetic Foot Ulcer Treatment
Epidemiology and Patient Population of Diabetic Foot Ulcer
Patient Journey of Diabetic Foot Ulcer
Diabetic Foot Ulcer Marketed Therapies
Diabetic Foot Ulcer Emerging Drugs
Diabetic Foot Ulcer: 7MM Analysis
Unmet Needs of Diabetic Foot Ulcer
SWOT Analysis of Diabetic Foot Ulcer
KOL Views of Diabetic Foot Ulcer
Market Access and Reimbursement of Diabetic Foot Ulcer
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-dfus-market
